Intrathecally Administered Indicator Fluids for Cranio-Spinal Clearance Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools to measure and quantify the clearance of substances from the cranio-spinal cavity in humans, assess movement of substances within and from the cerebrospinal fluid (CSF) compartment, and visualize the extra-vascular space of the brain and spinal cord, which is crucial for understanding neurological diseases and conditions such as Alzheimer's and multiple sclerosis.
Innovation Solution
The use of indicator fluids, such as CT and MRI contrast agents, and radioactive ligands, administered intrathecally, to assess the movement and clearance of substances by measuring their levels in blood and urine over time, and visualizing their movement through imaging modalities like CT, MRI, PET, and SPECT, allowing for the determination of clearance curves and visualization of extra-vascular spaces without disrupting the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods are used, then general anatomical visualization is achieved, but quantification of substance clearance and movement in the cranio-spinal cavity cannot be performed
Solution Approach 1:
The patent introduces indicator fluids as intermediary substances that are administered into the cranio-spinal cavity to enable measurement. These indicator fluids serve as mediators between the substance clearance process and the imaging detection system, allowing quantification of clearance rates through imaging of the indicator fluid's movement and distribution over time
Solution Approach 2:
The patent utilizes changes in imaging parameters (signal intensity, concentration levels) of the indicator fluid over time to quantify substance clearance. By measuring parameter changes in the indicator fluid distribution through sequential imaging, the system can calculate clearance rates and movement dynamics without directly measuring the endogenous substances
2Adaptability or versatility
If intravenous contrast agents are used, then blood pool visualization is achieved, but assessment of CSF compartment and extra-vascular space movement is not possible
Solution Approach 1:
The patent segments the assessment into different anatomical compartments (CSF compartment, brain tissue compartment, extra-vascular space) by using specific indicator fluids with different distribution characteristics. Each compartment can be assessed independently by selecting appropriate indicator fluids that preferentially distribute to or move through specific compartments, allowing versatile multi-compartment assessment without barrier disruption
Solution Approach 2:
The patent uses indicator fluids as intermediaries that can be administered intrathecally to assess CSF compartment dynamics without disrupting the blood-brain barrier. These indicator fluids act as mediators that trace substance movement through the CSF and into extra-vascular spaces, enabling assessment of compartments that are inaccessible to conventional intravenous contrast agents
3Loss of information
If substance clearance is not measured, then routine imaging is maintained, but understanding of neurological disease mechanisms is limited
Solution Approach 1:
The patent enables continuous assessment of substance clearance by performing sequential imaging at multiple time points after indicator fluid administration. This continuous monitoring of indicator fluid distribution and elimination provides ongoing information about clearance function, transforming a static imaging procedure into a dynamic functional assessment without significantly increasing procedural complexity
Solution Approach 2:
The patent incorporates feedback mechanisms where the measured clearance rates and movement patterns of the indicator fluid provide information about underlying physiological function. This feedback can be used to assess disease mechanisms (e.g., impaired clearance in neurological disorders) and potentially guide treatment decisions, adding diagnostic value to the imaging procedure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the quantification of substance clearance and movement within the cranio-spinal cavity, providing insights into neurological diseases and conditions, and allowing for the assessment of the cranio-spinal cavity's ability to remove waste products, thereby aiding in the understanding and potential treatment of conditions like Alzheimer's and multiple sclerosis.
Implementation Method 1
The indicator fluid may be a CT or MRI contrast agent
Implementation Method 2
The indicator fluid may be a CT or MRI contrast agent
Implementation Method 3
The indicator fluid may be a radioactive ligand
Data Source
AI summary
The present invention discloses indicator fluids, reference indicator fluid, and usage thereof, and systems and methods for assessing movement of molecular substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a human cranio-spinal cavity. Indicator fluid moving from the cerebrospinal fluid compartment enables measurements of levels of indicator fluid in blood or urine and assessment of the cranio-spinal cavity's ability to remove molecular substances. The indicator fluids may be contrast agents used for imaging, such as by computed tomography imaging, and magnetic resonance imaging, or imaging utilizing radioactive substances by positron emission tomography, single-photon emission computed tomography or scintigraphy. Using these imaging modalities, the invention describes indicator fluids, systems and methods enabling assessment of movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity, and from the human cranio-spinal cavity to lymphatic pathways or kidneys.